Semi-Annual Consolidated Statement Of Income

BrightPath Biotherapeutics Co., Ltd. - Filing #7559979

Concept 2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2021-04-01 to
2022-03-31
2021-04-01 to
2022-03-31
2021-04-01 to
2022-03-31
2021-04-01 to
2022-03-31
Semi-annual consolidated statement of income
Statement of income
Net sales
5,280,000 JPY
15,408,000 JPY
Cost of sales
1,895,000 JPY
3,317,000 JPY
Ordinary profit (loss)
-1,473,774,000 JPY
-1,481,945,000 JPY
Gross profit (loss)
3,384,000 JPY
12,091,000 JPY
Selling, general and administrative expenses
Remuneration for directors (and other officers)
58,300,000 JPY
52,300,000 JPY
Depreciation
10,000 JPY
15,000 JPY
Selling, general and administrative expenses
1,470,443,000 JPY
1,488,124,000 JPY
Extraordinary income
JPY
5,912,000 JPY
Extraordinary losses
9,958,000 JPY
5,738,000 JPY
Operating profit (loss)
-1,467,059,000 JPY
-1,476,033,000 JPY
Profit (loss) before income taxes
-1,483,733,000 JPY
-1,481,772,000 JPY
Income taxes - current
1,900,000 JPY
2,420,000 JPY
Non-operating income
Interest income
20,000 JPY
27,000 JPY
Non-operating income
567,000 JPY
117,000 JPY
Non-operating expenses
Non-operating expenses
7,283,000 JPY
6,029,000 JPY
Income taxes
1,900,000 JPY
2,420,000 JPY
Extraordinary income
Gain on sale of non-current assets
JPY
13,000 JPY
Profit (loss)
-1,485,633,000 JPY
-1,485,633,000 JPY
-1,485,633,000 JPY
-1,485,633,000 JPY
-1,484,192,000 JPY
-1,484,192,000 JPY
-1,484,192,000 JPY
-1,484,192,000 JPY
Extraordinary losses
Impairment losses
9,958,000 JPY
5,701,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.